SAN DIEGO, Sept. 29, 2016 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX) today announced the appointment
of Dr. Bruce L.A. Carter to the
Company's Board of Directors where he will also serve as a member
of the Audit Committee and Compensation Committee, effective
immediately.
"It is a privilege to welcome such a respected and accomplished
professional to our board of directors," said Charles M. Baum, M.D., Ph.D., president and CEO
of Mirati. "Bruce brings a great deal of experience gained as a
former CEO and seasoned pharmaceutical executive whose expertise
and leadership will make a significant contribution as we
aggressively advance our pipeline, including our three clinical
stage programs."
"I believe that Mirati will transform the treatment of patients
with cancer using drugs that target the very specific genetic
changes that drive tumor growth," said Dr. Carter. "Joining the
team at this juncture provides a great opportunity to work with
respected leaders in oncology drug development and contribute to
the Company's growth strategy."
Dr. Carter has extensive governing experience as an executive
and leader in the pharmaceutical and biotechnology industries,
having served as President and CEO of ZymoGenetics and as Executive
Vice President and Chief Scientific Officer of Novo Nordisk.
Dr. Carter most recently served as the Executive Chairman of Immune
Design Corp. and previously as a director of multiple biotechnology
companies, including as non-executive Chairman of the Board of
ZymoGenetics when it was sold to Bristol-Myers Squibb in
2010. Dr. Carter currently serves as Board Chairman for
Enanta Pharmaceuticals and for Xencor, Inc., and as a director of
Dr. Reddy's Laboratories in India.
Dr. Carter is also an Affiliate Professor, Department of
Biochemistry at the University of Washington,
Seattle, Washington and serves
as Board Chair of the Infectious Disease Research Institute in
Seattle, Washington and is on the
Board of Directors of the TB Alliance. Dr. Carter received a
B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in
Microbiology from Queen Elizabeth
College, University of London.
About Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing a pipeline of targeted oncology
products intended to treat specific genetic and epigenetic drivers
of cancer in selected subsets of cancer patients with unmet needs.
Our clinical pipeline consists of three product candidates:
glesatinib, sitravatinib and mocetinostat. Both glesatinib and
sitravatinib are orally bio-available, spectrum-selective kinase
inhibitors with distinct target profiles that are in development
for the treatment of patients with NSCLC and other solid tumors.
Glesatinib is in Phase 2 clinical development, and targets the MET
and Axl receptor tyrosine kinase families. Sitravatinib is in Phase
1b clinical development and targets genetic alterations in the RET
rearrangements, CHR4q12 amplifications, and CBL mutations. Our
third product candidate is mocetinostat, an orally bio-available,
Class 1 selective histone deacetylase inhibitor. Mocetinostat is in
Phase 2 clinical development in combination with durvalumab,
MedImmune's anti-PD-L1 immune checkpoint inhibitor, for the
treatment of patients with NSCLC. More information is available at
www.mirati.com.
Logo - http://photos.prnewswire.com/prnh/20160307/341355LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-announces-appointment-of-dr-bruce-la-carter-to-board-of-directors-300335429.html
SOURCE Mirati Therapeutics, Inc.